A
150.36
-0.84 (-0.56%)
| Penutupan Terdahulu | 151.20 |
| Buka | 152.13 |
| Jumlah Dagangan | 359,541 |
| Purata Dagangan (3B) | 542,834 |
| Modal Pasaran | 7,580,044,800 |
| Harga / Pendapatan (P/E Ke hadapan) | 370.37 |
| Harga / Jualan (P/S) | 13.09 |
| Harga / Buku (P/B) | 102.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | -64.39% |
| Margin Operasi (TTM) | -45.67% |
| EPS Cair (TTM) | -5.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 397.02% |
| Nisbah Semasa (MRQ) | 2.03 |
| Aliran Tunai Operasi (OCF TTM) | -118.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.98 M |
| Pulangan Atas Aset (ROA TTM) | -26.17% |
| Pulangan Atas Ekuiti (ROE TTM) | -282.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Axsome Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.10 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 16.31% |
| % Dimiliki oleh Institusi | 76.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alethea Capital Management, Llc | 30 Sep 2025 | 670,883 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 205.00 (Guggenheim, 36.34%) | Beli |
| Median | 190.50 (26.70%) | |
| Rendah | 154.00 (Needham, 2.42%) | Beli |
| Purata | 184.50 (22.71%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 133.45 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 06 Nov 2025 | 202.00 (34.34%) | Beli | 139.41 |
| Guggenheim | 04 Nov 2025 | 205.00 (36.34%) | Beli | 134.93 |
| HC Wainwright & Co. | 04 Nov 2025 | 185.00 (23.04%) | Beli | 134.93 |
| Morgan Stanley | 04 Nov 2025 | 196.00 (30.35%) | Beli | 134.93 |
| 20 Oct 2025 | 194.00 (29.02%) | Beli | 131.60 | |
| Needham | 04 Nov 2025 | 154.00 (2.42%) | Beli | 134.93 |
| RBC Capital | 04 Nov 2025 | 198.00 (31.68%) | Beli | 134.93 |
| Wells Fargo | 04 Nov 2025 | 157.00 (4.42%) | Beli | 134.93 |
| B. Riley Securities | 01 Oct 2025 | 179.00 (19.05%) | Beli | 118.57 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TABUTEAU HERRIOT | - | 145.98 | -79,973 | -11,541,516 |
| Jumlah Keseluruhan Kuantiti Bersih | -79,973 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -11,541,516 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 145.98 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Pegawai | 04 Dec 2025 | Jual automatik (-) | 10,558 | 148.04 | 1,563,006 |
| TABUTEAU HERRIOT | Pegawai | 04 Dec 2025 | Pelaksanaan pilihan | 10,558 | - | - |
| TABUTEAU HERRIOT | Pegawai | 03 Dec 2025 | Jual automatik (-) | 20,163 | 147.81 | 2,980,293 |
| TABUTEAU HERRIOT | Pegawai | 03 Dec 2025 | Pelaksanaan pilihan | 20,163 | - | - |
| TABUTEAU HERRIOT | Pegawai | 02 Dec 2025 | Jual automatik (-) | 49,252 | 142.09 | 6,998,217 |
| TABUTEAU HERRIOT | Pegawai | 02 Dec 2025 | Pelaksanaan pilihan | 49,252 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2025 | Pengumuman | Axsome Therapeutics to Participate in Upcoming Investor Conferences |
| 06 Nov 2025 | Pengumuman | Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy |
| 06 Nov 2025 | Pengumuman | Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics |
| 03 Nov 2025 | Pengumuman | Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 22 Oct 2025 | Pengumuman | Axsome Therapeutics to Participate in Upcoming Investor Conferences |
| 09 Oct 2025 | Pengumuman | Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community |
| 07 Oct 2025 | Pengumuman | Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 |
| 17 Sep 2025 | Pengumuman | Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |